RNA binding motif protein 22Genealiases: Cwc2 · ZC3H16 · fSAP47
Q-omics provides the consensus-scored RBM22 profile across patient tissues and cancer cell-line models. RBM22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM22 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RBM22 protein abundance shows 34,071 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RBM22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM22 survival associations across molecular data types. RBM22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM22 RNA expression–survival associations across cancer types. High RBM22 expression shows unfavorable associations in LIHC, KIRP, HNSC and LUSC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM22 RNA expression.
This table summarizes RBM22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM22 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, STAD and CHOL. The KIRC box plot shows higher RBM22 RNA expression in tumor versus normal tissue (log2 FC = +0.643, t-test p < 0.001).
This table shows molecular features associated with RBM22 in patient tissues and cancer cell lines. In patient samples, RBM22 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
